)  has been awarded a $63.3-million contract from the US Department of Health and  Human Services (HHS) for the development of pre-pandemic and pandemic flu  vaccines. The contract supports GSK’s ongoing pandemic vaccine research  studying the use of the company’s adjuvant technology in combination with  antigens to induce a strong immune response. 

Under the terms of the contract, GSK will engage in research  and development leading to licensure of antigen-sparing pre-pandemic and  pandemic vaccines with adjuvant that will help the US government extend the  limited North American supply of pandemic flu vaccines to protect larger  populations in the event of a flu pandemic. The five-year contract also gives  the government the option to fund an additional $44 million of future clinical  development programs related to antigen-sparing pandemic vaccines. 

News

GlaxoSmithKline (London, UK, www.gsk.com) has been awarded a $63.3-million contract from the US Department of Health and Human Services (HHS) for the development of pre-pandemic and pandemic flu vaccines.